New CPTAC Center Network Study Reveals Biomarker Method That Could Increase the Number of Diagnostic Tests for Cancer
A team of CPTAC researchers has demonstrated that a new method for detecting and quantifying protein biomarkers in body fluids may ultimately make it possible to screen multiple biomarkers in hundreds of patient samples, thus ensuring that only the strongest biomarker candidates will advance down the development pipeline. The study results, published in the online version of Nature Biotechnology on June 28, 2009, show that new applications of existing proteomic techniques show promise of greater accuracy and may eliminate a major roadblock in the development of diagnostic tests for cancer.
Read more
CPTC Leads Data Sharing Policy Efforts: The Amsterdam Principles
Working with the international community, CPTC has led efforts to provide recommendations for rapid proteomics data release and sharing policies that are similar to the Bermuda Principles, which served as a catalyst in the world of genomics. Read the white paper.
Data Sharing Policies Being Recognized as Important for Innovation
In a recent Scientific American worldVIEW article, "Sharing the Wealth of Data," Dr. Rodriguez helps shed light on the importance of data sharing policies, stating that "advances in science and healthcare are made possible through widespread and barrier-free access to research and the data produced by that research." Read the article.
New Funding through the American Recovery and Reinvestment Act (ARRA)
The NCI has launched a dedicated Web site in response to the American Recovery and Reinvestment Act of 2009 (ARRA), including funding opportunities in proteomics. Read more
Proteomics Podcast – The Promise of Proteomics for Personalized Medicine
Dr. Henry Rodriguez, Director of CPTC, offers his perspective on the potential for using new proteomics research to significantly advance the field of cancer research and to develop targeted therapies. Read more
Promise and Reality of Proteomics Webinar
Dr. Henry Rodriguez, Director of CPTC, and other speakers discuss the challenges facing clinical proteomics and the innovative ways that NCI's Clinical Proteomic Technologies for Cancer (CPTC) aims to develop new, more refined, efficient, and reliable biomarker discovery and verification pipelines. Read more
